Perchlorate

Perchlorate

SCHEMBL502589

CC[n+]1c(C=CC=Cc2ccc(N(C)C)cc2)ccc2cc(N(C)C)ccc21.[O-][Cl+3]([O-])([O-])[O-]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.62
RAB9A P51151 11/20 0.62
MEN1 O00255 11/20 0.62
HTT P42858 8/20 0.62
NPSR1 Q6W5P4 6/20 0.62
POLB P06746 6/20 0.62
L3MBTL1 Q9Y468 5/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
LMNA P02545 4/20 0.62
ALDH1A1 P00352 4/20 0.62
BLM P54132 3/20 0.62
PPARG P37231 2/20 0.62
NCOA2 Q15596 2/20 0.62
NCOA1 Q15788 2/20 0.62
NPC1 O15118 8/20 0.53
MAPT P10636 7/20 0.53
NSD2 O96028 4/20 0.53
MAPK1 P28482 4/20 0.53
THRB P10828 3/20 0.53
PKM P14618 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Perchlorate SCHEMBL29419033 1.00 KMT2A (0.62) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL2948028 0.95 KMT2A (0.67) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL21796187 0.95 KMT2A (0.67) KMT2ARAB9AMEN1HTTNPSR1
Perchlorate SCHEMBL4877794 0.83 KMT2A (0.88) KMT2ARAB9AMEN1HTTNPSR1
Perchlorate SCHEMBL4877802 0.83 KMT2A (0.88) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL10036041 0.83 KMT2A (0.83) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL31018271 0.78 KMT2A (0.97) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL5676065 0.78 KMT2A (0.97) KMT2ARAB9AMEN1HTTNPSR1
SCHEMBL5676060 0.78 KMT2A (0.97) KMT2ARAB9AMEN1HTTNPSR1
Hydrochloric Acid SCHEMBL11551422 0.77 KMT2A (0.95) KMT2ARAB9AMEN1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227326-A1 Detection System THE SECRETARY OF STATE FOR DEFENCE (GB) 2010-09-09 US claimed
EP-1390542-B1 NUCLEIC ACID DETECTION METHOD SECR DEFENCE (GB) 2005-06-29 EP claimed
US-20040241679-A1 Detection system SECRETARY OF STATE FOR DEFENCE, THE (GB) 2004-12-02 US claimed
EP-1390542-A2 NUCLEIC ACID DETECTION METHOD The Secretary of State DSTL (GB) 2004-02-25 EP claimed
WO-2002097132-A2 NUCLEIC ACID DETECTION METHOD THE SECRETARY OF STATE FOR DEFENCE (GB) 2002-12-05 WO claimed
EP-0731179-A2 A method for carrying out a laboratory test of the in vitro integrity of haematic cells with no fixation and/or permeabilization, by DNA and general nucleic acid labeling and by flow cytometry reading Petraroli, Salvatore (IT) 1996-09-11 EP claimed
US-20200182863-A1 NOVEL ANTIBODY CONJUGATES SUITABLE FOR USE IN DISCRETE FLUORESCENCE QUENCHING DISPLACEMENT IMMUNOASSAYS LIFE SCIENCE INKUBATOR SACHSEN GMBH & CO. KG (DE) 2020-06-11 US disclosed
US-9180209-B2 Non-peptidic quenched fluorescent imaging probes THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-11-10 US disclosed
US-8968700-B2 Imaging of protease activity in live cells using activity based probes THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-03-03 US disclosed
US-8105791-B2 Marker for stem cells and its use XINTELA AB (SE) 2012-01-31 US disclosed
US-20110033923-A1 MARKER FOR STEM CELLS AND ITS USE XINTELA AB 2011-02-10 US disclosed
US-20100227326-A1 Detection System THE SECRETARY OF STATE FOR DEFENCE (GB) 2010-09-09 US disclosed
US-7700275-B2 Detection system THE SECRETARY OF STATE OF DEFENSE (GB) 2010-04-20 US disclosed
US-20070036725-A1 Imaging of protease activity in live cells using activity based probes THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2007-02-15 US disclosed
EP-1390542-B1 NUCLEIC ACID DETECTION METHOD SECR DEFENCE (GB) 2005-06-29 EP disclosed
US-20040241679-A1 Detection system SECRETARY OF STATE FOR DEFENCE, THE (GB) 2004-12-02 US disclosed
EP-1390542-A2 NUCLEIC ACID DETECTION METHOD The Secretary of State DSTL (GB) 2004-02-25 EP disclosed
WO-2002097132-A2 NUCLEIC ACID DETECTION METHOD THE SECRETARY OF STATE FOR DEFENCE (GB) 2002-12-05 WO disclosed
EP-0731179-A2 A method for carrying out a laboratory test of the in vitro integrity of haematic cells with no fixation and/or permeabilization, by DNA and general nucleic acid labeling and by flow cytometry reading Petraroli, Salvatore (IT) 1996-09-11 EP disclosed
EP-0193356-B1 METHOD FOR ANALYSIS OF SUBPOPULATIONS OF BLOOD CELLS Becton Dickinson and Company (US) 1991-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070036725-A1 Imaging of protease activity in live cells using activity based probes CTSE, CTSK, CTSZ KMT2A 2993/4885RAB9A 1469/4885MEN1 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.